Lv32
316 积分 2022-10-15 加入
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
2个月前
已完结
JAK–STAT pathway targeting for the treatment of inflammatory bowel disease
3个月前
已完结
Engineering CAR-T therapies for autoimmune disease and beyond
3个月前
已完结
Deciphering the response to BCMA CAR T cell therapy
3个月前
已完结
Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunity
3个月前
已完结
CAR T cells produced in vivo to treat cardiac injury
3个月前
已完结
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
3个月前
已完结
Concentration of evobrutinib, a BTK inhibitor, in cerebrospinal fluid during treatment of patients with relapsing multiple sclerosis in a phase 2 study
4个月前
已完结
Enhanced Bruton's Tyrosine Kinase Activity in Peripheral Blood B Lymphocytes From Patients With Autoimmune Disease
4个月前
已完结
Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: analysis of body surface area involvement in the phase 3 POETYK PSO-1 and PSO-2 trials
4个月前
已关闭
皖公网安备34019202002308
